Factor X Antibody (AHX-5050): sc-81739

Factor X Antibody (AHX-5050) is a mouse monoclonal IgG1 kappa light chain antibody that detects Factor X protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-Factor X antibody (AHX-5050) is available as a non-conjugated format. Coagulation Factor X, also known as Stuart Prower factor, is a crucial component in the blood coagulation cascade, playing a vital role in hemostasis following tissue injury. This vitamin K-dependent serine protease is synthesized in the liver and circulates as an inactive precursor until activated through cleavage by either Factor IX A or Factor VII A. The activation process transforms Factor X into Factor X A, which is essential for forming the prothrombinase complex alongside Factor V A and calcium ions on platelet or endothelial cell surfaces. This complex converts prothrombin into active thrombin, a key step in generating fibrin clots and platelet aggregation. Deficiencies in Factor X due to mutations at the Factor X locus can lead to serious bleeding disorders, highlighting Factor X ′s critical role in maintaining hemostatic balance.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Factor X Antibody (AHX-5050) References:

1. Crystal structures of the membrane-binding C2 domain of human coagulation factor V.  |  Macedo-Ribeiro, S., et al. 1999. Nature. 402: 434-9. PMID: 10586886
2. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1.  |  Chambers, RC., et al. 2000. J Biol Chem. 275: 35584-91. PMID: 10952976
3. Severe factor X deficiency due to a homozygous mutation (Cys364Arg) that disrupts a disulphide bond in the catalytic domain.  |  Todd, T., et al. 2006. Haemophilia. 12: 621-4. PMID: 17083512
4. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.  |  Yang, YH., et al. 2006. J Immunol. 177: 8219-25. PMID: 17114499
5. Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX.  |  Ndonwi, M., et al. 2007. J Biol Chem. 282: 15632-44. PMID: 17387172
6. Analysis of the novel factor X gene mutation Glu51Lys in two families with factor X-Riyadh anomaly.  |  Al-Hilali, A., et al. 2007. Thromb Haemost. 97: 542-5. PMID: 17393015
7. The coagulation cascade: initiation, maintenance, and regulation.  |  Davie, EW., et al. 1991. Biochemistry. 30: 10363-70. PMID: 1931959
8. Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells.  |  Sierko, E., et al. 2012. Thromb Res. 129: e112-8. PMID: 22424030
9. Basic mechanisms in blood coagulation.  |  Davie, EW. and Fujikawa, K. 1975. Annu Rev Biochem. 44: 799-829. PMID: 237463
10. Site-specific functional roles of the Factor X activation peptide in the intrinsic tenase-mediated Factor X activation.  |  Carnbring Bonde, A., et al. 2022. FEBS Lett. 596: 1567-1575. PMID: 35181908
11. An Inherited Allele Confers Prostate Cancer Progression and Drug Resistance via RFX6/HOXA10-Orchestrated TGFβ Signaling.  |  Zhong, M., et al. 2024. Adv Sci (Weinh). 11: e2401492. PMID: 38932472
12. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S.  |  Di Scipio, RG., et al. 1977. Biochemistry. 16: 698-706. PMID: 836809

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Factor X Antibody (AHX-5050) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-Factor X Antibody (AHX-5050) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Factor X Antibody (AHX-5050) Specifications

Alternate Product Name: Factor X

Product Clone Name: AHX-5050

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: Factor X

Epitope Species: human

Product Reactivity/Detection: heavy chains of Factor X and X A

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide, 0.1% gelatin and 5% glycerol

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for Factor X Antibody (AHX-5050): L: Azide-Free